Through our blog, we hope to create a community where we can support and challenge each other through conversations, discussions and storytelling, and work together to move the field of oncology forward.

  • Looking at oncology – and ASCO – through a different lens

    This article was originally published on LinkedIn. It’s that time of year again, and I’m feeling a little shocked at the realization that a whole year has passed since I started sharing my perceptions and observations of the oncology landscape through this forum. It’s been a year of change for me professionally – a …

    Continue Reading

  • Pan-tumor biomarkers are key to some of today’s most remarkable cancer breakthroughs. One such biomarker is microsatellite instability (MSI), which plays an important role in immunotherapy treatment for advanced colorectal cancer patients. In the last four years, for example, the FDA approved two …

    Continue Reading

  • Uncovering Insights in Pancreatic and Prostate Cancers

    Most know a pancreatic cancer diagnosis is devastating. We’ve seen Patrick Swayze, Michael Landon, and Steve Jobs taken too soon by this terrible disease. We know survival is rare. Only 9 percent of patients live five years after diagnosis.1 Many may not realize, however, that prostate cancer can also be devastating, …

    Continue Reading

  • The Journal of the American Medical Association (JAMA) today published the validation study of our clinico-genomic database (CGDB), showing that real-world clinico-genomic data obtained during the course of routine patient care can yield scientifically and clinically meaningful insights. The study ‒ “Association of …

    Continue Reading

  • The most significant advances in cancer treatment start with a deep understanding of cancer biology; yet, even these biologically-driven hypotheses must be empirically validated given the complexity of the human body. This is why today immunotherapy treatments, which harness the power of our own immune systems, or …

    Continue Reading

  • Recognizing Value Through Collaboration

    As adoption of comprehensive genomic profiling (CGP) becomes more widespread in cancer treatment, new research is redefining the clinical utility of diagnostic tests in this age of precision medicine. The value of CGP lies in helping to inform decisions on available treatment options, including clinical trial …

    Continue Reading

  • Measuring the Value of Matched Therapy

    Broad molecular tumor profiling can offer clinical benefits to many cancer patients. This is further supported by the addition of broad genomic profiling to oncology practice guidelines, like the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in melanoma and non-small cell lung cancer (NSCLC). Now, …

    Continue Reading

  • Shifting the Treatment Paradigm in Blood Cancers: New Insights

    For decades, the approach to treating diseases like acute leukemia, lymphoma, and myeloma was based on assigning patients to prognostic groups and making uniform treatment decisions within that group. But with comprehensive genomic profiling, we can begin to unravel the heterogeneity within each group and develop more …

    Continue Reading

  • Personalized: Lung cancer’s present offers a glimpse at cancer’s future

    The impact of precision medicine on cancer treatment becomes more apparent each day. If you consider the patient experience, you start to see how much has changed already — and how much more is possible. When I began caring for patients with non-small cell lung cancer (NSCLC) about 30 years ago, the major therapeutic …

    Continue Reading

  • Expanding options for more patients: Introducing FoundationOne®Liquid

    With a single tissue biopsy and comprehensive genomic profiling (CGP), people diagnosed with cancer have access to more information about their disease than ever before. These insights are rapidly advancing precision medicine and giving patients the chance to find the treatment most likely to benefit their specific …

    Continue Reading